Loading market dashboard
Brainstorm Cell Therapeutics Inc.
BCLIHealthcareOTCUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehrig Day and reflects on the courage and resilience of those living with the disease, the publication highlights the growing need for regulatory approaches that keep pace with advances in science and the urgent realities faced by patients and families.
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately.
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing: The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69.
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update. "The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS," said Chaim Lebovits, President and CEO.
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Profitability This table compares Brainstorm Cell
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $0.66 and traded as high as $0.9479. Brainstorm Cell Therapeutics shares last traded at $0.85, with a volume of 8,002 shares
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn into a Phase 3b confirmatory study, having received clearance from the FDA in 2025 for the planned study," said Chaim Lebovits, President and CEO.
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.65 and traded as high as $0.90. Brainstorm Cell Therapeutics shares last traded at $0.87, with a volume of 9,450 shares. Brainstorm Cell Therapeutics Stock
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.28) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page
